CERO CERo Therapeutics Holdings, Inc.
Debt Financing ·
CERo Therapeutics Holdings agreed on October 6, 2026 to sell its operating subsidiary to SRX Global Inc. The buyer would discharge the Consolidated Note, which had an outstanding principal balance of $8,249,643.77.
The note combines earlier notes and lets SRX advance up to $6,000,000 in total at 10% interest. Principal and interest are due October 15, 2026.
CERo Therapeutics expanded its convertible note with SRX Global to $2,085,200. The note carries 10% interest, matures May 28, 2027, and converts at the lesser of $0.05 and 80% of recent trading lows.
CERo Therapeutics amended a note with SRX Health Solutions, Inc. that converts into common stock at a price set by recent trading. The maximum is $1,413,600, of which $663,600 was funded on June 23, 2026.
The note was sold for $750,000 and bears 10% interest, with conversion at the lesser of $0.05 or a discount to recent trading prices.
CERo Therapeutics Holdings issued a convertible promissory note to Keystone Capital Partners, LLC on April 27, 2026, with a purchase price of $400,000 and a principal face value of $500,000.
Nasdaq staff set a September 8, 2025 delisting date. CERo requested a hearing on September 3, 2025, which stays the suspension, and plans to present a compliance plan.
The company needs more time to value marketable securities it received as part payment for Series D Preferred Stock. It estimates an $18.5 million net loss for the quarter and a $33.4 million loss attributable to common shareholders.
About $5 million is expected at the first closing. The company said the money will also help address Nasdaq shareholders' equity deficiencies.
| Line | FY2025 | FY2023 |
|---|---|---|
| Research and development | $5.3 million | |
| Net income (loss) | -$19.9 million | -$7.3 million |
| Cash from operations | -$16.1 million | -$1.5 million |
| Cash and equivalents | $1.7 million | $96,873 |
Our latest story on this, dated Sep 4, 2025: "CERo Therapeutics appeals Nasdaq delisting over $2,500,000 stockholders' equity rule". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 14, 2026: "CERo Therapeutics expands SRX Global convertible note to $2,085,200". The story links the filing or release it is based on. Read the story.
CERo Therapeutics Holdings, Inc. trades under the ticker CERO on OTC.
CERo Therapeutics Holdings, Inc. is listed on OTC.
The SEC Central Index Key (CIK) for CERo Therapeutics Holdings, Inc. is 1870404. Its filings are on SEC EDGAR.
71,630,992 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-14.
Our directory records CERo Therapeutics Holdings, Inc. under United States.
Our directory classifies CERo Therapeutics Holdings, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for CERo Therapeutics Holdings, Inc. is US71902K4022.
aibio.space lists CERo Therapeutics Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
CERo Therapeutics Holdings, Inc. reported a net loss of $19.9 million for the fiscal year ended Dec 31, 2025, and used $16.1 million of cash in operations, per its annual report to the SEC.
$862,756 in cash at Jun 30, 2026, per its 10-Q.
Our latest story on CERo Therapeutics Holdings, dated Oct 7, 2026: "CERo agrees to sell operating unit to SRX Global". CERo Therapeutics Holdings agreed on October 6, 2026 to sell its operating subsidiary to SRX Global Inc. The buyer would discharge the Consolidated Note, which had an outstanding principal balance of $8,249,643.77. Source.
Our latest financing story, dated Apr 22, 2025: "CERo Therapeutics signs up to $8 million Series D convertible preferred financing". About $5 million is expected at the first closing. The company said the money will also help address Nasdaq shareholders' equity deficiencies. Source.
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,1.02,2.03,3.02,9.01). Source
Filed to remove its shares from exchange listing. SEC Form 25-NSE. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a change of independent auditor. SEC Form 8-K (Items 1.01,2.03,3.02,4.01,5.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,8.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.03,7.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio